2. Neurological Disease

Neurological Disease

Neurological Disease

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. 상품명 CAS No. Purity 화학구조
  • HY-105090
    Lerisetron 143257-98-1 99.69%
    Lerisetron is a potent 5-HT3 antagonists and possess high-affinity binding for the 5-HT3 receptors with pKi value of 9.2. Lerisetron has a potent ability to inhibit the 5-HT-evoked reflex bradycardia in urethane-anesthetized rats.
    Lerisetron
  • HY-105542
    Niaprazine 27367-90-4 99.48%
    Niaprazine is a histamine H1-receptor antagonist. Niaprazine has antihistamine and antiserotonin activities and can be used for sleep disorder research.
    Niaprazine
  • HY-105692
    DR2313 284028-90-6 99.66%
    DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of poly(ADP-ribose) polymerase (PARP), with IC50s of 0.20 μM and 0.24 μM for PARP-1 and PARP-2, respectively. DR2313 exhibits neuroprotective effects on ischemic injuries in vitro and in vivo.
    DR2313
  • HY-105860
    Selurampanel 912574-69-7 99.28%
    Selurampanel (BGG 492) is an orally active and competitive AMPA receptor antagonist with an IC50 of 190 nM. Selurampanel has reasonable blood-brain barrier penetration. Selurampanel can be used for epilepsy research.
    Selurampanel
  • HY-106316
    CGS 20625 111205-55-1 99.80%
    CGS 20625 is a potent, selective and orally active partial agonist for the central benzodiazepine receptor. CGS 20625 inhibits [3H]-flunitrazepam binding to central benzodiazepine receptors with an IC50 of 1.3 nM. CGS 20625 enhances GABA in Xenopus laevis oocytes . CGS 20625 can be used for the research of pentylenetetrazol-induced seizures and anxiety.
    CGS 20625
  • HY-106408
    Nelonemdaz 640290-67-1 99.84%
    Nelonemdaz (Salfaprodil free base) is an NR2B-selective and uncompetitive antagonist of N-methyl-D-aspartate (NMDA). Nelonemdaz is also a free radical scavenger. Nelonemdaz has excellent neuroprotection against NMDA- and free radical-induced cell death.
    Nelonemdaz
  • HY-106454
    N-Desalkylflurazepam 2886-65-9 99.95%
    N-Desalkylflurazepam (Norfludiazepam) is a long-acting metabolite of benzodiazepine compounds, such as Flurazepam. N-Desalkylflurazepam inhibits L-type voltage-gated calcium channels with IC50 values of 55 μM and 37 μM for Cav1.2 and Cav1.3, respectively.
    N-Desalkylflurazepam
  • HY-106617
    Etoperidone 52942-31-1 98%
    Etoperidone, an antidepressant agent, is an orally active serotonin and nor-adrenaline re-uptake antagonist. Etoperidone shows Kd values of 36 nM, 38 nM, 85 nM, and 570 nM for 5-HT2 receptor, α1-adrenergic receptor, 5-HT1A receptor, and α2-adrenergic receptor, respectively.
    Etoperidone
  • HY-106770
    Esuprone 91406-11-0 99.67%
    Esuprone is a brain-penetrant, orally active and selective MAO A inhibitor with an IC50 of 7.3 nM. Esuprone can be used for neurological research.
    Esuprone
  • HY-106809
    BMY-21502 123259-91-6 98.98%
    BMY-21502 (BMS-181168) is a pyrrolidinone derivative with memory- and cognition-enhancing activities. BMS-181168 attenuates hypoxia-induced deterioration in brain function, as delta/theta decreases, alpha activity increases and the centroid of the combined delta/theta waves is accelerated.
    BMY-21502
  • HY-106822
    Losigamone 112856-44-7 99.94%
    Losigamone (AO-33) is an orally active antiepileptic compound. Losigamone blocks sodium channel. Losigamone stimulates the neuronal chloride channel and enhance chloride influx. Losigamone potentiates GABA-mediated responses and reduces epileptiform activity induced by chloride channel antagonists. Losigamone can be used for epilepsy research.
    Losigamone
  • HY-107275
    Ebeiedinone 25650-68-4 99.51%
    Ebeiedinone, a steroidal alkaloid from Fritillaria species, inhibits the bioactivity of human whole blood cholinesterase (ChE) at the concentration of 0.1 mM, with the inhibitory effects of 69.0%.
    Ebeiedinone
  • HY-107423
    GNE 6901 1698900-69-4 99.31%
    GNE 6901 (compound 40) is a potent GluN2A-selective NMDAR positive allosteric modulator (PAM) with an EC50 of 382 nM.
    GNE 6901
  • HY-107503
    MMPIP 479077-02-6 99.38%
    MMPIP is an allosteric metabotropic glutamate receptor 7 (mGluR7) selective antagonist (KB values 24 -30 nM). MMPIP acts as a pharmacological tool for elucidating the roles of mGluR7 on central nervous system functions. MMPIP alleviates pain and normalizes affective and cognitive behavior in neuropathic mice.
    MMPIP
  • HY-107504
    VU0360172 hydrochloride 1309976-62-2 98.94%
    VU0360172 hydrochloride is a potent and selective mGlu5 receptor positive allosteric modulator (PAM) with an EC50 value of 16 nM and a Ki of 195 nM, respectively. VU0360172 hydrochloride stimulates polyphosphoinositide (PI) hydrolysis in vivo, which is abrogated in mGlu5 receptors gene deleted mice.
    VU0360172 hydrochloride
  • HY-107509
    LY2389575 hydrochloride 885104-09-6 99.93%
    LY2389575 hydrochloride is a selective and noncompetitive mGlu3 negative allosteric modulator (NAM), with an IC50 value of 190 nM. LY2389575 hydrochloride induces an increase in Mrc1 levels. LY2389575 hydrochloride also independently amplifies Amyloid beta (Aβ) toxicity and can be used in study of Alzheimer's disease.
    LY2389575 hydrochloride
  • HY-107514
    (RS)-PPG 120667-15-4 99.76%
    (RS)-PPG is a potent and selective agonist for group III mGluRs. The EC50s of 5.2 μM, 4.7 μM, 185 μM, and 0.2 μM for hmGluR4a, hmGluR6, hmGluR7b, and hmGluR8a, respectively. Anticonvulsive and neuroprotective activity.
    (RS)-PPG
  • HY-107624
    ATC0175 510733-97-8 99.70%
    ATC0175 is a potent, selective and orally active melanin-concentrating hormone 1 recepter antagonist with IC50s of 13.5, >10000 nM for MCH1R, MCH2R, respectively. ATC0175 shows antidepressant effects and anxiolytic effects in animal models. ATC0175 has the potential for the research of depression and/or anxiety disorders.
    ATC0175
  • HY-107645
    DAU 5884 hydrochloride 131780-48-8 99.0%
    DAU 5884 hydrochloride is a potent muscarinic M3 receptor antagonist. DAU 5884 hydrochloride inhibits methacholine-dependent effects on cell proliferation and muscle contractility.
    DAU 5884 hydrochloride
  • HY-107652
    AF-DX 384 118290-26-9 98.0%
    AF-DX 384 is a selective antagonist of M2 and M4 muscarinic acetylcholine receptors (Kis=6.03 and 10 nM, respectively). AF-DX 384 reverses deficits in novel object recognition and passive avoidance in aged rats, as well as in young rats with impairments induced by scopolamine.
    AF-DX 384
Cat. No. 상품명 / Synonyms Application Reactivity